(Q35904441)

English

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

19 December 2019

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

19 December 2019

breast neoplasm

1 reference

19 December 2019

tumor biomarker

1 reference

7 August 2019

marker of proliferation Ki-67

1 reference

19 December 2019

1 reference

based on heuristic

inferred from title

Frédérique Penault-Llorca

6

object named as

Frédérique Penault-Llorca

0 references

Patricia de Cremoux

24

object named as

Patricia de Cremoux

0 references

Brigitte Sigal-Zafrani

8

object named as

Brigitte Sigal-Zafrani

0 references

2

object named as

Fabrice André

0 references

Jocelyne Jacquemier

5

object named as

Jocelyne Jacquemier

0 references

Nicole Tubiana Mathieu

7

object named as

Nicole Tubiana-Mathieu

0 references

author name string

Elisabeth Luporsi

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Frédérique Spyratos

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Pierre-Marie Martin

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Nicole Tubiana-Mathieu

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Brigitte Sigal-Zafrani

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Laurent Arnould

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Anne Gompel

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Caroline Egele

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Bruno Poulet

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Krishna B Clough

13

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hubert Crouet

14

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Alain Fourquet

15

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jean-Pierre Lefranc

16

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Carole Mathelin

17

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Nicolas Rouyer

18

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Daniel Serin

19

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Marc Spielmann

20

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Margaret Haugh

21

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Marie-Pierre Chenard

22

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Etienne Brain

23

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Patricia de Cremoux

24

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jean-Pierre Bellocq

25

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

3 November 2011

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 April 2012

6 references

13 March 2019

3 April 2019

19 June 2019

17 June 2019

7 August 2019

19 December 2019

Breast Cancer Research and Treatment

7 references

Europe PubMed Central

PMC publication ID

11 August 2017

13 March 2019

3 April 2019

19 June 2019

17 June 2019

7 August 2019

19 December 2019

132

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

895-915

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Cancer biomarkers: can we turn recent failures into success?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Recent advances: adjuvant therapy for older women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Current and emerging biomarkers in breast cancer: prognosis and prediction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Personalized treatment of early-stage breast cancer: present concepts and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Ki67 in breast cancer: prognostic and predictive potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Letrozole in the neoadjuvant setting: the P024 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Common markers of proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Proliferation marker Ki-67 in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Comparison of Ki-67 equivalent antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

MIB-1 labelling index is an independent prognostic marker in primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

11 July 2018

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Prognostic value of different factors in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3332349

24 September 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1837-Z

21 January 2018

A simple index using video image analysis to predict disease outcome in primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dichotomizing continuous predictors in multiple regression: a bad idea

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative validation of the SP6 antibody to Ki67 in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the Ki-67 labelling index ready for clinical use?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22048814

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-011-1837-Z

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35904441&oldid=2197944997"